載入中
NASDAQHealthcareBiotechnology
最新資料
US$3.31
−US$0.11 · -3.22%
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
前收盤價
US$3.31
−US$0.11 · -3.22%
盤中時間採用ET。市場資料可能有所延遲。
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
日內區間
目前US$3.31
52週區間
目前US$3.31
盤中時間採用ET。市場資料可能有所延遲。
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
日內區間
目前US$3.31
52週區間
目前US$3.31
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1.21億 USD | 7310.7萬 USD | 5628.6萬 USD | — | — |
| 銷售、一般及管理費用 | 2462萬 USD | 775.6萬 USD | 848.5萬 USD | 3520 USD | 4.34萬 USD |
| 營業費用 | 1.46億 USD | 8086.3萬 USD | 6477.1萬 USD | 3520 USD | 4.34萬 USD |
| 利息收入 | 1134.3萬 USD | 637.7萬 USD | 7.2萬 USD | — | — |
| 折舊和攤銷 | 61萬 USD | 20.8萬 USD | 9.2萬 USD | 3520 USD | — |
| 營業利益 | −1.46億 USD | −8086.3萬 USD | −6477.1萬 USD | −3520 USD | −4.34萬 USD |
| 淨利 | −1.34億 USD | −7427.5萬 USD | −6469.9萬 USD | −3520 USD | −4.34萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$19.00
上漲空間 474.02%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1252.15萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF491.01萬0.01%954億 USD0.05%US$235+0.80%
State Street SPDR S&P Biotech ETFXBI228.24萬0.02%98.74億 USD0.35%US$153.77+3.00%
iShares Biotechnology ETFIBB126.83萬0.01%108.2億 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA77.75萬0.00%218.24億 USD0.03%US$32.79+0.40%
Virtus Biotech Clinical Trials ETFBBC14萬0.34%4099.65萬 USD0.65%US$44.1456+2.08%
Direxion Daily S&P Biotech Bull 3X SharesLABU10.79萬0.02%5.97億 USD0.96%US$243.09+9.01%
Schwab U.S. Broad Market ETFSCHB9.48萬0.00%453.77億 USD0.03%US$29.91+0.61%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFState Street SPDR S&P Biotech ETFXBIiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVirtus Biotech Clinical Trials ETFBBCDirexion Daily S&P Biotech Bull 3X SharesLABUSchwab U.S. Broad Market ETFSCHBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
